Secretome Therapeutics raises $30M Series A from RA Capital for Duchenne cardiomyopathy therapy
What's the deal? Secretome Therapeutics, a clinical-stage biotech based in Plano, Texas, has closed a $30 million Series A financing led solely by RA Capital Management. The funds will advance its lead candidate, STM-01 — a therapy derived from neonatal cardiac progenitor cells (nCPCs) — toward pivotal Phase 2 and Phase 3 trials for cardiomyopathy associated with Duchenne muscular dystrophy.
Duchenne is a rare, progressive muscle-wasting disease with few disease-modifying treatments, and heart failure is one of its leading causes of death. STM-01 aims to become the first cell-based therapy to meaningfully alter the cardiac trajectory for these patients.
Why now? The financing comes as Secretome prepares to move from early clinical work into late-stage development — a capital-intensive leap. RA Capital, which specialises in evidence-based healthcare investing, was the sole investor, signalling strong conviction in the science.
Industry veteran David Lubner has joined Secretome's board as part of the deal. Lubner brings over 25 years of biotech leadership, including stints as chief financial officer at Ra Pharmaceuticals (acquired by UCBDealroom has a profile for this one. Try Dealroom → in 2020) and Tetraphase Pharmaceuticals, plus board seats at companies acquired by Gilead, Biogen, and Eli Lilly. Matthew Hammond, a partner at RA Capital, will serve as a board observer.
What could go wrong? Cell-based therapies face steep regulatory and manufacturing hurdles. Pivotal trials in rare diseases are notoriously difficult to enrol, and $30 million may not stretch far enough to complete both Phase 2 and Phase 3 programmes without additional capital.
Secretome is also betting on a narrow initial indication. If clinical results disappoint, the entire nCPC platform — which the company hopes to extend to other rare cardiomyopathies — could lose credibility with investors.
The signal: RA Capital's decision to sole-fund this Series A at $30 million underscores a growing willingness among specialist healthcare funds to make concentrated bets on rare disease platforms, even at the early-revenue stage. Secretome, classified as a "breakout" company on Dealroom, is positioning its nCPC platform at the intersection of two high-conviction investor themes — cell therapy and rare cardiac disease — where clinical differentiation could make it an attractive acquisition target for larger biopharma players.
Read more: BusinessWire
